AIA Group Ltd Purchases 96,372 Shares of CVS Health Corporation $CVS

AIA Group Ltd lifted its position in shares of CVS Health Corporation (NYSE:CVS) by 389.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 121,145 shares of the pharmacy operator’s stock after acquiring an additional 96,372 shares during the period. AIA Group Ltd’s holdings in CVS Health were worth $9,133,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in CVS. Strategic Investment Advisors MI increased its stake in shares of CVS Health by 5.2% in the 3rd quarter. Strategic Investment Advisors MI now owns 8,544 shares of the pharmacy operator’s stock valued at $644,000 after purchasing an additional 420 shares during the last quarter. Keel Point LLC lifted its position in shares of CVS Health by 9.1% during the 3rd quarter. Keel Point LLC now owns 4,128 shares of the pharmacy operator’s stock worth $311,000 after buying an additional 345 shares during the last quarter. FNY Investment Advisers LLC boosted its stake in CVS Health by 393.3% in the third quarter. FNY Investment Advisers LLC now owns 2,807 shares of the pharmacy operator’s stock valued at $211,000 after buying an additional 2,238 shares in the last quarter. Severin Investments LLC grew its position in CVS Health by 124.9% in the third quarter. Severin Investments LLC now owns 14,789 shares of the pharmacy operator’s stock valued at $1,115,000 after acquiring an additional 8,212 shares during the last quarter. Finally, Allworth Financial LP raised its stake in CVS Health by 7.2% during the third quarter. Allworth Financial LP now owns 28,764 shares of the pharmacy operator’s stock worth $2,169,000 after acquiring an additional 1,922 shares in the last quarter. 80.66% of the stock is owned by institutional investors.

CVS Health Trading Down 2.4%

NYSE CVS opened at $73.03 on Thursday. The firm has a market capitalization of $92.91 billion, a PE ratio of 52.92, a price-to-earnings-growth ratio of 0.78 and a beta of 0.49. The business’s 50-day moving average price is $77.83 and its two-hundred day moving average price is $77.83. The company has a current ratio of 0.84, a quick ratio of 0.63 and a debt-to-equity ratio of 0.80. CVS Health Corporation has a 12 month low of $58.35 and a 12 month high of $85.15.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The company had revenue of $105.69 billion during the quarter, compared to the consensus estimate of $103.67 billion. During the same period last year, the company earned $1.19 earnings per share. The firm’s revenue was up 8.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. On average, analysts expect that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Thursday, January 22nd were paid a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.6%. The ex-dividend date of this dividend was Thursday, January 22nd. CVS Health’s dividend payout ratio is currently 192.75%.

Wall Street Analysts Forecast Growth

CVS has been the topic of a number of research analyst reports. Leerink Partners restated an “outperform” rating and issued a $98.00 price target on shares of CVS Health in a research note on Thursday, March 5th. The Goldman Sachs Group raised their target price on shares of CVS Health from $95.00 to $97.00 and gave the company a “buy” rating in a research report on Thursday, February 12th. Piper Sandler reaffirmed an “overweight” rating and set a $101.00 target price (up from $99.00) on shares of CVS Health in a research note on Wednesday, December 10th. Truist Financial set a $100.00 price target on CVS Health in a research note on Wednesday, December 10th. Finally, Royal Bank Of Canada reissued an “outperform” rating on shares of CVS Health in a report on Thursday, December 4th. Twenty analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $95.05.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.